Navigation Links
Yale Cancer Center Joins OncLive's Strategic Alliance Partnership

Plainsboro, N.J. (PRWEB) July 15, 2014

OncLive® is pleased to announce that Yale Cancer Center has joined its Strategic Alliance Partnership program.

Participating in the Strategic Alliance Partnership program will enable Yale Cancer Center to work with the OncLive team to raise awareness of its efforts to deliver patient-centered care, achieve breakthrough discoveries, and train future leaders in cancer science and medicine.

Yale Cancer Center has been a National Cancer Institute (NCI)-designated comprehensive cancer center for more than 40 years, and is one of only 41 such organizations in the country. Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven have 12 multidisciplinary cancer programs, a robust portfolio of advanced clinical trials, and offer patients and their families, expert and compassionate care. Treatment at Yale increasingly places an emphasis on targeted therapies incorporating a patient’s particular cancer subtype and genetic profile.

In addition to providing cutting-edge personalized, multidisciplinary cancer care, Yale Cancer Center clinicians and scientists make significant contributions in basic and translational research. Research at Yale includes programs in developmental therapeutics, cancer genetics and genomics, molecular virology, cancer immunology, signal transduction, cancer prevention and control, and radiobiology. Yale researchers are engaged in projects designed to encourage collaborative research, such as the Cancer Biology Institute.

Mike Hennessy, Jr., Vice President of Sales and Marketing and leader of the oncology division of Intellisphere, the publisher of OncLive, said, “Yale Cancer Center has long been a pioneer in cancer treatment and drug development. We look forward to partnering with such a renowned and prestigious institution that shares our mission of supporting oncologists, nurses, and other oncology professionals in their efforts to provide the highest quality care and improve the quality of life of patients with cancer.”

To date, more than 20 cancer centers, nursing schools, and other groups have joined OncLive’s Strategic Alliance Partnership program.

To learn more about OncLive, visit


About OncLive® is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, and Contemporary Oncology. The mission of OncLive® and its family of publications is to provide oncology professionals with the resources and information they need in order to provide the best care for their patients. The Oncology Specialty Group is a division of Intellisphere, LLC, a leading provider of health care publishing, research, and education. To learn more, please visit

About Yale Cancer Center
Yale Cancer Center and Smilow Cancer Hospital aim to prevent and cure cancer through groundbreaking research, scientific discovery, and compassionate patient care. The collaboration of over 450 scientists and physicians focused on cancer research at Yale Cancer Center provides a strong foundation for breakthroughs in cancer prevention, diagnosis, and treatment. Yale Cancer Center seeks to capitalize on the scientific strengths of Yale University to benefit cancer patients throughout the world, while providing the very best in clinical cancer care to our patients at Smilow Cancer Hospital at Yale-New Haven.

Media Contact:
Allie Artur
For OncLive
267-932-8760 x304 (office)

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
2. Simple blood test can detect lung cancer with high sensitivity and specificity - results from large clinical validation study published in the Journal of Clinical Oncology
3. Leading Cancer Immunotherapy Biotech Startup Announces New Investments, Leadership Appointments
4. Generex Announces Completion of Enrollment of Antigen Express Phase II AE37 Breast Cancer Vaccine Trial
5. Exosome Diagnostics and QIAGEN Expand Collaboration to Develop Non-Invasive Biofluid Diagnostic for Lung Cancer
6. Science Magazine: Cancer Immunotherapy is the Medical Breakthrough of 2013; The CBCD Highlights the Link between Immunotherapy and Microcompetition
7. A Unique Collaboration of Life Science Leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, has formed Triphase Accelerator Corporation to be an Oncology Development Accele
8. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
9. BerGenBio Presents Data at AACR-ISLAC Conference on the Molecular Origins of Lung Cancer
10. ReachMD Launches New Oncology Show Featuring Well-known Cancer Expert and Host, Selma Schimmel
11. Piggy-backing proteins ride white blood cells to wipe out metastasizing cancer
Post Your Comments:
(Date:11/27/2015)... 2015 --> ... companion diagnostics is one of the major ... pharmaceutical companies and diagnostic manufacturers working together ... . --> ... global cancer biomarkers market spread across 89 ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
(Date:10/27/2015)... Germany , October 27, 2015 ... SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically maps ... SMI,s Eye Tracking Glasses , so that they ... BeGaze. --> Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ...
Breaking Biology News(10 mins):